Pre-close period Trading Upda

RNS Number : 3650F

Dechra Pharmaceuticals PLC

12 January 2010

 



Issued by Citigate Dewe Rogerson Ltd, Birmingham

Date:  Tuesday, 12 January 2010

Dechra® Pharmaceuticals PLC

("Dechra" or "The Group")

Pre-close period Trading Update

The Board of Dechra issues the following trading update ahead of the publication of the Group's Half-Year Results for the six months ended 31 December 2009 which are scheduled to be announced on Tuesday 23 February 2010.

Trading Update

Group revenue for the six months ended 31 December 2009 was approximately 6.5% ahead of the equivalent period last year.

Pharmaceuticals Division

Overall revenue from this division was approximately 12.6% higher than the equivalent period in 2008.

Our lead pharmaceutical product, Vetoryl®, continued to show good growth in all markets including sales for the six months of $2.5 million in the USA, where over 25% of companion animal practices (approximately 7,000) have now purchased the product.

Our diets range, branded Specific®, showed solid growth across Europe.

Dales Pharmaceuticals, our manufacturing business, made good progress in the period increasing its revenue from third party customers.

Services Division

Revenue from this division for the six months ended 31 December 2009 was 4.6% up on the equivalent period in the prior year with the growth rate being higher in the second quarter than the first quarter. Effective cost control at our distribution business, NVS®, ensured that the operating margin has continued to be maintained at the level achieved for the year ended 30 June 2009.

Summary

Trading in the first half of the financial year has been in line with management's expectations. Despite continuing economic uncertainty, there are indications of volume growth starting to return to the market. This growth, together with the continued penetration of our own branded products, impending new product launches in the EU and a robust development pipeline, enables the Board to look to the future with optimism.

Enquiries:
Ian Page, Chief Executive	Fiona Tooley, Director
Simon Evans, Group Finance Director	Keith Gabriel, Senior Account Manager
Dechra Pharmaceuticals PLC	Citigate Dewe Rogerson
Telephone: + 44 (0) 1782 771100	Telephone: [phone]
Mobile: [phone] (IP)	Mobile: [phone] (FT)
Mobile: [phone] (SE)	Mobile: [phone] (KG)

[e-mail]

Ticker: Sector: Full Listing (Pharmaceuticals): DPH

Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

TSTFMGMMVMNGGZM